Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TIGIT and Anti-PDL1 in Recurrent Glioblastoma
NCT06328036Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of tiragolumab in glioblastoma (GBM), sponsored by National Cancer Institute. Planned start Apr 2025; status: withdrawn.
02
Drugs
tiragolumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06328036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328036.